Panel discussions
This panel will explore the journey of a medication from early innovation to market authorization, highlighting Swissmedic’s key support mechanisms. Topics include the Innovation Office, scientific advice for clinical trials, fast-track pathways for unmet patient needs, continuous engagement with developers, pipeline meetings, regulatory clarifications as well as international collaboration and harmonization to enhance patient access to innovative treatments.
May 6, 16:00 - 16:45, room Marriott 1+2
| Name | Position | Institution |
|---|---|---|
| Eliane Schmid | Head of Communication | Swissmedic, Swiss Agency for Therapeutic Products |
| Name | Position | Institution |
|---|---|---|
| Benoît Dubuis | President | Fondation INARTIS |
| Laura Andrea Wyss | Associate Director Regulatory Strategy | Moderna Switzerland |
| Sandra Zaugg | Head Division Regulatory Assessment | Swissmedic |
| Julia Djonova | Head of Division Advanced Therapy Medicinal Products | Swissmedic |
| Deana Mohr | Project Leader | MUVON Therapeutics, ETH Zürich |
Swissmedic is the national authorisation and supervisory authority for drugs and medical products. The agency ensures that only high-quality, safe and effective medical products are available in Switzerland, thus making an important contribution to the protection of human and animal health.
